Landscape Capital Management L.L.C. Takes $615,000 Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

Landscape Capital Management L.L.C. bought a new position in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 65,525 shares of the biotechnology company's stock, valued at approximately $615,000.

Several other hedge funds have also modified their holdings of the stock. Perceptive Advisors LLC lifted its position in Iovance Biotherapeutics by 34.6% during the 2nd quarter. Perceptive Advisors LLC now owns 25,933,142 shares of the biotechnology company's stock valued at $207,984,000 after purchasing an additional 6,660,151 shares during the period. Long Focus Capital Management LLC lifted its holdings in Iovance Biotherapeutics by 195.1% in the second quarter. Long Focus Capital Management LLC now owns 4,132,000 shares of the biotechnology company's stock valued at $33,139,000 after buying an additional 2,731,688 shares during the period. Vanguard Group Inc. boosted its stake in Iovance Biotherapeutics by 9.2% in the first quarter. Vanguard Group Inc. now owns 24,915,300 shares of the biotechnology company's stock valued at $369,245,000 after acquiring an additional 2,102,480 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Iovance Biotherapeutics by 60.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 5,267,864 shares of the biotechnology company's stock worth $78,071,000 after acquiring an additional 1,991,262 shares during the period. Finally, Marshall Wace LLP bought a new stake in shares of Iovance Biotherapeutics during the 2nd quarter valued at $12,929,000. 77.03% of the stock is owned by institutional investors.

Insider Transactions at Iovance Biotherapeutics

In other Iovance Biotherapeutics news, Director Ryan D. Maynard sold 50,000 shares of Iovance Biotherapeutics stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $10.06, for a total value of $503,000.00. Following the sale, the director now directly owns 7,500 shares in the company, valued at approximately $75,450. The trade was a 86.96 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 12.10% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on IOVA. Piper Sandler downgraded Iovance Biotherapeutics from an "overweight" rating to a "neutral" rating and dropped their price objective for the company from $19.00 to $10.00 in a report on Monday, July 29th. HC Wainwright reiterated a "buy" rating and issued a $32.00 price target on shares of Iovance Biotherapeutics in a research report on Wednesday, November 6th. StockNews.com upgraded shares of Iovance Biotherapeutics to a "sell" rating in a report on Monday, August 12th. Finally, UBS Group began coverage on shares of Iovance Biotherapeutics in a report on Thursday, October 24th. They issued a "buy" rating and a $17.00 target price on the stock. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the stock. According to MarketBeat, Iovance Biotherapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $22.33.

Iovance Biotherapeutics Stock Up 3.8 %

Shares of NASDAQ:IOVA traded up $0.31 during midday trading on Friday, reaching $8.55. 9,273,848 shares of the company were exchanged, compared to its average volume of 8,788,478. The firm has a market cap of $2.61 billion, a PE ratio of -5.74 and a beta of 0.60. Iovance Biotherapeutics, Inc. has a fifty-two week low of $5.41 and a fifty-two week high of $18.33. The stock has a fifty day simple moving average of $9.91 and a two-hundred day simple moving average of $9.52.

Iovance Biotherapeutics (NASDAQ:IOVA - Get Free Report) last issued its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.28) EPS for the quarter, beating analysts' consensus estimates of ($0.31) by $0.03. Iovance Biotherapeutics had a negative return on equity of 58.43% and a negative net margin of 451.25%. The company had revenue of $58.56 million for the quarter, compared to analyst estimates of $53.54 million. During the same period in the previous year, the company posted ($0.46) earnings per share. As a group, analysts forecast that Iovance Biotherapeutics, Inc. will post -1.25 earnings per share for the current year.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.